July 10, 2020
AliExpress WW
Coronavirus: UK begins trial of new vaccine in humans

Coronavirus: UK begins trial of new vaccine in humans

AliExpress WW

Vaccine candidate

Image copyright
Imperial College

Volunteers began immunization with a new British coronavirus vaccine.

AliExpress WW

About 300 people will receive the vaccine over the coming weeks as part of a study conducted by Professor Robin Shattock and his colleagues at Imperial College London.

Animal tests show that the vaccine is safe and elicits an effective immune response.

Experts from Oxford University have already begun human trials.

Tests are being conducted in many countries around the world – currently about 120 vaccination programs are being conducted.

“I volunteered to help defeat the virus”

Media playback not supported on your device

Media headlineKatie is one of the first 300 volunteers to take part in this test phase.

Katie, 39, working in finance, is one of the first volunteers to take part in the imperial process.

She said that she volunteered because she wanted to play a role in the fight against the virus.

“I think this was due to the fact that I did not know what I could do to help, and this turned out to be what I could do.

“And realizing that it is unlikely that everything will return to normal until the vaccine appears, so we also want to be part of this progress.”

After this first stage, another test is planned for October with the participation of 6,000 people.

The imperial team hopes that the vaccine can be distributed in the UK and abroad from the beginning of 2021.

meanwhile Duke of Cambridge Meets Volunteers participating in the lawsuit of the University of Oxford at Churchill City Hospital.

Prince William told the volunteers: “This is the most incredibly exciting and highly coveted project you all do, so it’s fun.”

New approach

Many traditional vaccines are based on a weakened or modified form of the virus or part thereof, but the imperial vaccine is based on a new approach using synthetic strands of the genetic code, called RNAs, that mimic the virus.

After injection into the muscle, RNA self-amplifies, generating its own copies, and instructs its own cells to make copies of the spike protein found outside the virus.

This should teach the immune system to recognize and fight coronavirus without developing Covid-19.

Since the imperial vaccine uses only a small amount of the genetic code, a little goes very far. The imperial team says that one liter of its synthetic material will be enough to produce two million doses.

These doses were produced in the United States, but later this year production switches to the UK, so that if and when it is needed for mass production, this can be done here.

All clinical trials begin cautiously and slowly to reduce safety risks. When the Oxford vaccine began in April, only two volunteers were immunized on the first day. During the week, 100 people were weaved every day.

The unique nature of the imperial vaccine means that only one volunteer is immunized on the first day, and then three more every 48 hours. After about a week, the numbers will gradually increase.

Unlike the Oxford vaccine, which uses a single dose, volunteers participating in the imperial trial will receive two vaccinations with an interval of four weeks.

Prof. Shattock and his team say they have no particular security concerns – this is simply the novelty of the approach, which forces them to act cautiously.

There are over 120 early-stage coronavirus vaccines worldwide. Most of them will never go outside the laboratory. Another 13 are undergoing clinical trials: five in China, three in the United States, two in the UK, one in Australia, Germany and Russia.

All vaccination teams seek to emphasize that they are not in a race against each other, but against the virus. If there are enough doses to protect the world, several approaches to vaccines should be successful.

Professor Shattock said: “We were able to produce the vaccine from scratch and bring it to the test in humans in just a few months.

“If our approach works and the vaccine provides effective protection against disease, it can fundamentally change our response to outbreaks of disease in the future.”

Image caption

Chief Investigator Dr. Katrina Pollock hopes the vaccine will work

The lead investigator, Dr. Katrina Pollock, added: “I would not have worked on this test if I hadn’t felt cautious optimism that we would see an excellent immune response among our participants.”

“The preclinical data looked very promising. We get a neutralizing antibody response, which is an immune response that you would like to protect against infection. But there is still a long way to go to evaluate this vaccine. ”

The study was funded by 41 million pounds from the UK government, as well as 5 million pounds from other donations.


Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: